A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...

The CSF1R-blocking antibody axatilimab has shown promising clinical activity in chronic GVHD. In this phase 2, multinational, pivotal, randomized study, we evaluated axatilimab at three different ...

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting ...

Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier. In August, the FDA approved axatilimab (Niktimvo; Incyte) to treat chronic graft-versus-host disease ...

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody for the ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple ...

More information: Daniel Wolff et al, Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease, New England Journal of Medicine (2024).DOI: 10.1056/NEJMoa2401537 Mohamad Mohty ...

The US Food and Drug Administration (FDA) has approved axatilimab (Niktimvo, Incyte Corporation and Syndax) for the treatment of adult and pediatric patients with chronic graft versus host disease ...

Syndax Pharmaceuticals has upcoming Q3 PDUFAs for revumenib and axatilimab, both awarded priority review. Syndax pegs both upcoming PDUFAs as potential blockbusters once approved, with revumenib ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...